Transcript profiling distinguishes complete treatment responders with locally advanced cervical cancer.
Cervical cancer (CC) mortality is a major public health concern since it is the second cause of cancer-related deaths among women. Patients diagnosed with locally advanced CC (LACC) have an important rate of recurrence and treatment failure. Conventional treatment for LACC is based on chemotherapy and radiotherapy; however, up to 40% of patients will not respond to conventional treatment; hence, we searched for a prognostic gene signature able to discriminate patients who do not respond to the conventional treatment employed to treat LACC. Tumor biopsies were profiled with genome-wide high-density expression microarrays. Class prediction was performed in tumor tissues and the resultant gene signature was validated by quantitative reverse transcription-polymerase chain reaction. A 27-predictive gene profile was identified through its association with pathologic response. The 27-gene profile was validated in an independent set of patients and was able to distinguish between patients diagnosed as no response versus complete response. Gene expression analysis revealed two distinct groups of tumors diagnosed as LACC. Our findings could provide a strategy to select patients who would benefit from neoadjuvant radiochemotherapy-based treatment.
Laboratorio de Genomica, UBIMED, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico (UNAM), Tlalnepantla, Mexico; Laboratorio de Oncogenomica, Instituto Nacional de Cancerologia, Tlalpan, Mexico.
Jorge
J
Fernandez-Retana
Laboratorio de Oncogenomica, Instituto Nacional de Cancerologia, Tlalpan, Mexico.
Federico
F
Lasa-Gonsebatt
Laboratorio de Genomica, UBIMED, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico (UNAM), Tlalnepantla, Mexico.
Eduardo
E
Lopez-Urrutia
Unidad de Investigaciones Biomedicas en Cancer, Instituto Nacional de Cancerologia, Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de México (UNAM), Tlalpan, Mexico.
Jaime
J
Coronel-Martínez
Unidad de Investigaciones Biomedicas en Cancer, Instituto Nacional de Cancerologia, Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de México (UNAM), Tlalpan, Mexico.
David
D
Cantu De Leon
Unidad de Bioquimica, Instituto Nacional de Nutrición (INCMNSZ), Tlalpan, Mexico.
Nadia
N
Jacobo-Herrera
Direccion de Infecciones Cronicas y Cancer, Instituto Nacional de Salud Publica, Cuernavaca, México.
Oscar
O
Peralta-Zaragoza
Departmento de Anatomia Patologica, Instituto Nacional de Cancerologia, Tlaplan, Mexico.
Delia
D
Perez-Montiel
Unidad de Epidemiologia, Instituto Nacional de Cancerologia, Tlalpan, Mexico.
Nancy
N
Reynoso-Noveron
Servicio de Tumores de Mama, Subdirección de Cirugia, Instituto Nacional de Cancerologia, Tlalpan, Mexico.
Rafael
R
Vazquez-Romo
Laboratorio de Genomica, UBIMED, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico (UNAM), Tlalnepantla, Mexico; Laboratorio de Oncogenomica, Instituto Nacional de Cancerologia, Tlalpan, Mexico. Electronic address: carlos.pplas@gmail.com.
Carlos
C
Perez-Plasencia